Q-omics provides the consensus-scored RBMXP5 profile across patient tissues and cancer cell-line models. RBMXP5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBMXP5 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RBMXP5 RNA expression shows 14,282 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where RBMXP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMXP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMXP5 survival associations across molecular data types. RBMXP5 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMXP5 RNA expression–survival associations across cancer types. High RBMXP5 expression shows unfavorable associations in LIHC, ACC, KIRP and ESCA, but favorable associations in KIRC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBMXP5 RNA expression.
This table summarizes RBMXP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RBMXP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMXP5 shows higher tumor expression in COAD, LUSC, KIRC, LUAD, CHOL and READ. The COAD box plot shows higher RBMXP5 RNA expression in tumor versus normal tissue (log2 FC = +0.614, t-test p < 0.001).
This table shows molecular features associated with RBMXP5 in patient tissues and cancer cell lines. In patient samples, RBMXP5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
